ProCE Banner Activity

Podcast Pearls
Individualizing Care for Patients With Triple-Negative Breast Cancer

Podcast Episodes

Download this short slideset of key points from a podcast on current optimal approaches for the management of patients with TNBC.

Released: January 18, 2023

Expiration: January 17, 2024

No longer available for credit.

Share

Faculty

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Gilead Sciences, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark Pegram, MD: consultant/advisor/speaker: AstraZeneca/Daiichi Sankyo, Gilead Sciences, Roche/Genentech.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, AstraZeneca, ARC Therapeutics, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead Sciences, Infinity Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana Therapeutics, Myovant, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zymeworks; steering committee: CytomX, Lilly, OncXerna; researcher (paid to institution): AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead Sciences, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics.